Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 3
2008 2
2009 1
2010 7
2011 2
2012 3
2013 3
2014 3
2016 7
2017 10
2018 10
2019 9
2020 23
2021 20
2022 10
2023 11
2024 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Development and Validation of a Modified Full Age Spectrum Creatinine-Based Equation to Estimate Glomerular Filtration Rate : A Cross-sectional Analysis of Pooled Data.
Pottel H, Björk J, Courbebaisse M, Couzi L, Ebert N, Eriksen BO, Dalton RN, Dubourg L, Gaillard F, Garrouste C, Grubb A, Jacquemont L, Hansson M, Kamar N, Lamb EJ, Legendre C, Littmann K, Mariat C, Melsom T, Rostaing L, Rule AD, Schaeffner E, Sundin PO, Turner S, Bökenkamp A, Berg U, Åsling-Monemi K, Selistre L, Åkesson A, Larsson A, Nyman U, Delanaye P. Pottel H, et al. Among authors: garrouste c. Ann Intern Med. 2021 Feb;174(2):183-191. doi: 10.7326/M20-4366. Epub 2020 Nov 10. Ann Intern Med. 2021. PMID: 33166224 Free article.
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035. Epub 2020 Mar 6. Kidney Int. 2020. PMID: 32299680 Free article. Clinical Trial.
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.
Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D; 311 Study Group Members. Barbour T, et al. Kidney Int Rep. 2021 Mar 24;6(6):1603-1613. doi: 10.1016/j.ekir.2021.03.884. eCollection 2021 Jun. Kidney Int Rep. 2021. PMID: 34169200 Free PMC article.
Spondyloarthritis-Associated IgA Nephropathy.
Champtiaux N, Lioté F, El Karoui K, Vigneau C, Miceli C, Cornec-Le Gall E, Rémy P, Choukroun G, Fakhouri F, Garrouste C, Veillon L, Pillebout E, Lobbedez T, Vuiblet V, Wynckel A, Guincestre T, Toussirot E, Thervet E, Rabant M, Karras A. Champtiaux N, et al. Among authors: garrouste c. Kidney Int Rep. 2020 Mar 16;5(6):813-820. doi: 10.1016/j.ekir.2020.03.012. eCollection 2020 Jun. Kidney Int Rep. 2020. PMID: 32518863 Free PMC article.
Immunoallergic interstitial nephritis secondary to denosumab.
Philipponnet C, Kemeny JL, Aniort J, Garrouste C, Heng AE. Philipponnet C, et al. Among authors: garrouste c. Joint Bone Spine. 2018 Mar;85(2):253-254. doi: 10.1016/j.jbspin.2017.01.005. Epub 2017 Jan 20. Joint Bone Spine. 2018. PMID: 28115267 Review. No abstract available.
Gender heterogeneity in self-reported hypertension.
Bonsang E, Caroli E, Garrouste C. Bonsang E, et al. Among authors: garrouste c. Econ Hum Biol. 2021 Dec;43:101071. doi: 10.1016/j.ehb.2021.101071. Epub 2021 Oct 19. Econ Hum Biol. 2021. PMID: 34757302
Estimating glomerular filtration in young people.
Delanaye P, Derain-Dubourg L, Björk J, Courbebaisse M, Couzi L, Gaillard F, Garrouste C, Grubb A, Jacquemont L, Hansson M, Kamar N, Legendre C, Littmann K, Mariat C, Rostaing L, Rule AD, Sundin PO, Bökenkamp A, Berg U, Åsling-Monemi K, Åkesson A, Larsson A, Nyman U, Pottel H. Delanaye P, et al. Among authors: garrouste c. Clin Kidney J. 2024 Aug 28;17(9):sfae261. doi: 10.1093/ckj/sfae261. eCollection 2024 Sep. Clin Kidney J. 2024. PMID: 39314869 Free PMC article.
117 results